4-way competition in the Novel Oral Anticoagulant(NOAC) market

Competition is expected to be fiercer in the rapidly growing NOAC market.

As Daiichi Sankyo launched Lixiana with the insurance benefit on the 1^st of February, the 3-way competition among Xarelto, Pradaxa and Eliquis has been re-fueled in the oral NOAC(Novel Oral Anticoagulant) market.

According to UBIST, Bayer’s Xarelto(rivaroxaban) and Boehringer Ingelheim’s Pradaxa(dabigatran) achieved KRW...